{
    "info": {
        "nct_id": "NCT05386576",
        "official_title": "Venetoclax in Combination With Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
        "inclusion_criteria": "* Adult patients with newly diagnosed Philadelphia chromosome (Ph) negative ALL.\n* Patients with T- or B-cell lymphoblastic lymphoma with no bone marrow involvement will also be eligible for the study.\n* Age 18-60\n* ECOG performance status of 0-2\n* Adequate renal function as demonstrated by a calculated creatinine clearance of ≥ 60 ml/min.\n* Adequate hepatic function as demonstrated by a total bilirubin ≤ 2.0 mg/dl (unless attributable to Gilbert's disease) and an alkaline phosphatase, AST, and ALT ≤ 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)\n* Patients with central nervous system (CNS) involvement by ALL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice. For patients with CNS disease, dexamethasone may be temporarily administered instead of prednisone to reduce CNS pressure, at the discretion of the treating physician and after discussion with the MSK PI. Once dexamethasone is no longer needed, prednisone should be given as per protocol for 28 days.\n* Negative serum pregnancy test in women of childbearing potential\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
        "exclusion_criteria": "* CML in lymphoid blast crisis, mature B-cell (i.e. Burkitt's) lymphoma or mixed phenotype acute leukemia (MPAL)\n* Prior treatments for ALL, except any doses of corticosteroids and hydroxyurea or one dose of vincristine\n* Patients who received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment\n* Unstable angina and/or MI or stroke within 6 months prior to screening, and/or impaired cardiac function with EF <40% or NYHA class III/IV\n* Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.\n* Patients with HIV or active hepatitis B or hepatitis C infection are ineligible.\n* Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate renal function as demonstrated by a calculated creatinine clearance of ≥ 60 ml/min.",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function as demonstrated by a calculated creatinine clearance of ≥ 60 ml/min.",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "creatinine clearance",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative serum pregnancy test in women of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative serum pregnancy test",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function as demonstrated by a total bilirubin ≤ 2.0 mg/dl (unless attributable to Gilbert's disease) and an alkaline phosphatase, AST, and ALT ≤ 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function as demonstrated by a total bilirubin ≤ 2.0 mg/dl (unless attributable to Gilbert's disease)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase, AST, and ALT ≤ 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase, AST, and ALT ≤ 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase, AST, and ALT ≤ 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 60 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 60 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adult patients with newly diagnosed Philadelphia chromosome (Ph) negative ALL.",
            "criterions": [
                {
                    "exact_snippets": "Adult patients",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": "adult"
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed",
                    "criterion": "diagnosis status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis timing",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "Philadelphia chromosome (Ph) negative ALL",
                    "criterion": "acute lymphoblastic leukemia (ALL) subtype",
                    "requirements": [
                        {
                            "requirement_type": "Philadelphia chromosome status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with T- or B-cell lymphoblastic lymphoma with no bone marrow involvement will also be eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with T- or B-cell lymphoblastic lymphoma",
                    "criterion": "lymphoblastic lymphoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "T-cell",
                                "B-cell"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no bone marrow involvement",
                    "criterion": "bone marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with central nervous system (CNS) involvement by ALL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice. For patients with CNS disease, dexamethasone may be temporarily administered instead of prednisone to reduce CNS pressure, at the discretion of the treating physician and after discussion with the MSK PI. Once dexamethasone is no longer needed, prednisone should be given as per protocol for 28 days.",
            "criterions": [
                {
                    "exact_snippets": "Patients with central nervous system (CNS) involvement by ALL are eligible",
                    "criterion": "central nervous system (CNS) involvement by ALL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice",
                    "criterion": "concomitant treatment with radiation therapy and/or intrathecal chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with CNS disease, dexamethasone may be temporarily administered instead of prednisone to reduce CNS pressure, at the discretion of the treating physician and after discussion with the MSK PI",
                    "criterion": "temporary administration of dexamethasone instead of prednisone for CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Once dexamethasone is no longer needed, prednisone should be given as per protocol for 28 days",
                    "criterion": "prednisone administration after dexamethasone",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 18-60",
            "criterions": [
                {
                    "exact_snippets": "Age 18-60",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior treatments for ALL, except any doses of corticosteroids and hydroxyurea or one dose of vincristine",
            "criterions": [
                {
                    "exact_snippets": "Prior treatments for ALL, except any doses of corticosteroids and hydroxyurea or one dose of vincristine",
                    "criterion": "prior treatments for ALL",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "any doses of corticosteroids",
                                "hydroxyurea",
                                "one dose of vincristine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant or lactating women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant or lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use of effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with HIV or active hepatitis B or hepatitis C infection are ineligible.",
            "criterions": [
                {
                    "exact_snippets": "Patients with HIV ... are ineligible",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B ... are ineligible",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection ... are ineligible",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CML in lymphoid blast crisis, mature B-cell (i.e. Burkitt's) lymphoma or mixed phenotype acute leukemia (MPAL)",
            "criterions": [
                {
                    "exact_snippets": "CML in lymphoid blast crisis",
                    "criterion": "chronic myeloid leukemia (CML) in lymphoid blast crisis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "mature B-cell (i.e. Burkitt's) lymphoma",
                    "criterion": "mature B-cell lymphoma (Burkitt's lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "mixed phenotype acute leukemia (MPAL)",
                    "criterion": "mixed phenotype acute leukemia (MPAL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina and/or MI or stroke within 6 months prior to screening, and/or impaired cardiac function with EF <40% or NYHA class III/IV",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MI or stroke within 6 months prior to screening",
                    "criterion": "myocardial infarction or stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "prior to screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "impaired cardiac function with EF <40%",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "NYHA class III/IV",
                    "criterion": "NYHA class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years.",
            "criterions": [
                {
                    "exact_snippets": "Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy",
                    "criterion": "concurrent active malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring any therapy other than expectant observation or hormonal therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of squamous and basal cell carcinoma of the skin",
                    "criterion": "squamous and basal cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in situ cervical cancer",
                    "criterion": "in situ cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequately treated stage I/II cancer from which the patient is current in complete remission",
                    "criterion": "adequately treated stage I/II cancer",
                    "requirements": [
                        {
                            "requirement_type": "remission status",
                            "expected_value": "current in complete remission"
                        }
                    ]
                },
                {
                    "exact_snippets": "any other cancer from which the patient has been disease free for five years",
                    "criterion": "any other cancer",
                    "requirements": [
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients who received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment",
                    "criterion": "CYP3A inducer administration",
                    "requirements": [
                        {
                            "requirement_type": "strength",
                            "expected_value": [
                                "strong",
                                "moderate"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to the initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}